Sergio Quezada
20Patents
7h-index
20Co-inventors
65Inventor score
Filing activity: Apr 24, 2006 → Feb 5, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8236304B2 | Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity | Chemistry; Metallurgy | 27 | Active |
| US8709417B2 | Combination immunotherapy for the treatment of cancer | Chemistry; Metallurgy | 26 | Active |
| US8465740B2 | Regulatory T cell mediator proteins and uses thereof | Chemistry; Metallurgy | 23 | Active |
| US9375475B2 | Combination immunotherapy for the treatment of cancer | Chemistry; Metallurgy | 17 | Active |
| US10752691B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 10 | Active |
| US10738125B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 10 | Active |
| US10745485B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 10 | Active |
| US10023637B2 | Combination immunotherapy for the treatment of cancer | Chemistry; Metallurgy | 5 | Active |
| US10167337B2 | Combination immunotherapy for the treatment of cancer | Chemistry; Metallurgy | 3 | Active |
| US11098121B2 | “Immune checkpoint intervention” in cancer | Chemistry; Metallurgy | 2 | Active |
| US11802160B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 0 | Active |
| US8097249B2 | Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate D4+ and CD8+ T cell immunity | General | 0 | Revoked |
| US11851494B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11873341B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11814434B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11802161B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11697688B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11879014B2 | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody | Chemistry; Metallurgy | 0 | Active |
| US11787866B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 0 | Active |
| US11919960B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.